Skip to main navigation

Investors
News Releases
Events & Presentations
Stock Information
Corporate Governance
SEC Filings
IR Resources

News Releases

News Releases

Year

August 26, 2020

Harpoon Therapeutics Names Karin Ann Thacker, M.Sc., VP Regulatory Affairs and Quality Assurance

August 5, 2020

Harpoon Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

August 5, 2020

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

July 2, 2020

Harpoon Therapeutics Announces Changes to Board of Directors

June 17, 2020

Harpoon Therapeutics Updates Information for its Participation in Two Upcoming Virtual Conferences

June 11, 2020

Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences

May 29, 2020

Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

May 22, 2020

Harpoon Therapeutics to Present Interim Clinical Data for TriTAC® HPN424 at the ASCO20 Virtual Scientific Program

May 6, 2020

Harpoon Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update

April 27, 2020

Harpoon Therapeutics Doses First Patient with HPN217, a BCMA Targeting TriTAC, for Multiple Myeloma

Pagination

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
Next page
Last page

Email Alerts

RSS Feeds

Contact IR

Search

© 2022. Harpoon Therapeutics, Inc. All rights reserved.

Search Investor Relations